BioAge Labs, Inc. — Director's Dealing 2025

Dec 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioAge Labs, Inc. (BIOA)
CIK: 0001709941
Period of Report: 2025-12-04

Reporting Person: RUBIN PAUL D (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-04	Common Stock	M	68897	$4.11	Acquired	68897	Direct
2025-12-04	Common Stock	S	68897	$10.1878	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-04	Stock Option (Right to Buy)	$4.11	M	68897	Disposed	2030-06-30	Common Stock (68897)	Direct

Footnotes

F1: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.96 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

F3: This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.